Oracle and Ci4CC Partner to Accelerate Oncology Innovation

Rhea-AI Summary

Oracle (NYSE:ORCL) and the Cancer Center Informatics Society (Ci4CC) announced a strategic collaboration on Nov 7, 2025 to accelerate AI innovation in oncology.

The non-binding agreement aims to combine Oracle's AI-enabled health technology with Ci4CC's national network of NCI-Designated and community cancer centers to develop an EHR optimized for cancer care, integrate clinical and genomic data, enable AI-driven clinical trial approaches, and build real-world evidence and precision oncology platforms.

Insights

Health Informatics Strategist

Oracle and Ci4CC formed a strategic, non-binding collaboration to apply Oracle's AI and technology to cancer informatics and care.

Oracle will combine its technology with the Cancer Center Informatics Society's national network and Initiatives Program to pursue an EHR optimized for cancer care and to integrate clinical and genomic data for personalized medicine.

Planned workstreams include AI-driven clinical trial methods, real-world evidence frameworks, and precision oncology platforms; the agreement is explicitly non-binding, so execution and scope remain conditional on later commitments.

Key near-term items to watch are public disclosures of a cancer-specific EHR design, pilot projects with Ci4CC member centers, and any concrete governance or data‑sharing arrangements that define access to the Society's network; these items will clarify operational progress and practical impact.

Strategic collaboration to leverage Ci4CC's national network and Oracle's technology to help advance AI in oncology, EHR interoperability, next-gen clinical trials, and personalized medicine

MIAMI BEACH, Fla., Nov. 7, 2025 /PRNewswire/ -- 24th Cancer Center Informatics Society Symposium -- Oracle Health and Life Sciences and the Cancer Center Informatics Society (Ci4CC), a nonprofit uniting cancer centers, researchers, and industry innovators, are collaborating to advance AI innovation in oncology care and research.

The collaboration aims to bring together Oracle's technology with Ci4CC's Initiatives Program and national network of NCI-Designated and Community Care Cancer Centers. The two organizations plan to collaborate to design an EHR optimized for cancer care.  

"Cancer remains a leading cause of death worldwide, but AI and data science have become powerful allies in the fight," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "Combining Ci4CC's unparalleled expertise and network with our state-of-the-art proven AI-powered healthcare applications, we have the opportunity to accelerate discoveries that can help cure cancer."

The strategic collaboration intends to develop initiatives across oncology care and clinical research. This includes integrating clinical and genomic data for personalized medicine solutions, pioneering AI-driven approaches for clinical trial innovation and drug development, establishing robust real-world evidence frameworks, and advancing precision oncology platforms.

"This alliance with Oracle marks a significant milestone for Ci4CC and our mission to further cancer informatics," said Sorena Nadaf-Rahrov, MS, MMI, PhDc, President & CEO - Cancer Center Informatics Society. "Advancements in cancer research and clinical care are not achieved in isolation. That's why fostering such collaborative networks is fundamental to our Initiatives Program, and central to the Society's mission.

By integrating Oracle's cutting-edge and AI-enabled technology with real-world data from our national network of NCI-Designated and Community Cancer Centers, we hope to incubate and operationalize initiatives that will redefine cancer research and patient care. Turning data into knowledge, and knowledge into health continues to drive the Cancer Center Informatics Society forward."

The collaboration is part of a non-binding agreement.

For more information about Ci4CC visit: https://www.ci4cc.org/.
To learn more about Oracle's commitment to advancing health and life sciences, visit: https://www.oracle.com/life-sciences/ 

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-ci4cc-partner-to-accelerate-oncology-innovation-302608712.html

SOURCE Oracle

FAQ

What did Oracle (ORCL) announce on Nov 7, 2025 about oncology?

Oracle announced a strategic collaboration with Ci4CC to advance AI, EHR interoperability, clinical trial innovation, and precision oncology across a national cancer center network.

How will the Oracle and Ci4CC collaboration affect EHR systems for cancer care?

The partners plan to collaborate to design an EHR optimized for cancer care, integrating clinical and genomic data to support personalized medicine.

Is the Oracle–Ci4CC agreement binding and what is the timeline?

The announcement describes the collaboration as a non-binding agreement; no specific timeline was disclosed.

Will the Oracle and Ci4CC partnership involve AI-driven clinical trials and drug development?

Yes, the collaboration intends to pioneer AI-driven approaches for clinical trial innovation and drug development using integrated data and real-world evidence frameworks.

Which cancer centers will participate in the Oracle and Ci4CC initiatives?

The collaboration aims to leverage Ci4CC's national network of NCI-Designated and community cancer centers; individual center participation was not specified.

Where can investors find more information about Oracle's health initiatives related to this collaboration?

Investors can review Oracle's health and life sciences information on Oracle's life sciences web pages and Ci4CC's site for program details.